Dr. Steve Williamson, MD
Claim this profileThe University of Kansas Cancer Center (KUCC)
Studies Non-Small Cell Lung Cancer
Studies Bladder Cancer
5 reported clinical trials
8 drugs studied
Affiliated Hospitals
Clinical Trials Steve Williamson, MD is currently running
CRS-HIPEC
for Colorectal Cancer
The purpose of this trial is to compare the morbidity and mortality of CRS-HIPEC using mitomycin-C versus melphalan for colorectal peritoneal carcinomatosis. Morbidity and mortality will measured using the Comprehensive Complication Index (CCI) score, Common terminology criteria for adverse events (CTCAE version 4.03), and the Clavien-Dindo Classification.
Recruiting1 award Phase 2
Ipatasertib + Docetaxel
for Non-Small Cell Lung Cancer
For metastatic/advanced NSCLC patients who do not have targetable mutations, either immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in combination with platinum doublet chemotherapy is now a standard of care. However, still about half of the patients do not benefit due to treatment resistance. It is therefore critically important to find novel therapies and combinations to benefit patients who have failed or are intolerant to 1st line immunotherapy. This study hypothesizes that ipatasertib in combination with taxane (e.g. docetaxel) can be an effective strategy. Ipatasertib is a novel adenosine triphosphate (ATP)-competitive inhibitor that has demonstrated robust and selective targeting of protein kinase B (PKB, also known as AKT) in cancer patients. Importantly, evidence from preclinical studies has demonstrated that AKT inhibitors (e.g. ipatasertib) can enhance the therapeutic effect of chemotherapy as well as immunotherapy via modulating Phosphatidylinositol 3-kinase (PI3'K)-AKT activity.
Recruiting1 award Phase 210 criteria
More about Steve Williamson, MD
Clinical Trial Related2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Steve Williamson, MD has experience with
- Ascorbic Acid
- Mitomycin C
- Melphalan
- Ipatasertib
- Docetaxel
- Pembrolizumab
Breakdown of trials Steve Williamson, MD has run
Non-Small Cell Lung Cancer
Bladder Cancer
Peritoneal Tumors
Appendiceal Neoplasms
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Steve Williamson, MD specialize in?
Steve Williamson, MD focuses on Non-Small Cell Lung Cancer and Bladder Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Steve Williamson, MD currently recruiting for clinical trials?
Yes, Steve Williamson, MD is currently recruiting for 2 clinical trials in Fairway Kansas. If you're interested in participating, you should apply.
Are there any treatments that Steve Williamson, MD has studied deeply?
Yes, Steve Williamson, MD has studied treatments such as Ascorbic Acid, Mitomycin C, Melphalan.
What is the best way to schedule an appointment with Steve Williamson, MD?
Apply for one of the trials that Steve Williamson, MD is conducting.
What is the office address of Steve Williamson, MD?
The office of Steve Williamson, MD is located at: The University of Kansas Cancer Center (KUCC), Fairway, Kansas 66205 United States. This is the address for their practice at the The University of Kansas Cancer Center (KUCC).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.